SG176299A1 - Compositions and methods for administration of vaccines against dengue virus - Google Patents
Compositions and methods for administration of vaccines against dengue virus Download PDFInfo
- Publication number
- SG176299A1 SG176299A1 SG2011088788A SG2011088788A SG176299A1 SG 176299 A1 SG176299 A1 SG 176299A1 SG 2011088788 A SG2011088788 A SG 2011088788A SG 2011088788 A SG2011088788 A SG 2011088788A SG 176299 A1 SG176299 A1 SG 176299A1
- Authority
- SG
- Singapore
- Prior art keywords
- dengue virus
- composition
- subject
- vaccine
- den
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 81
- 229960005486 vaccine Drugs 0.000 title claims abstract description 74
- 241000725619 Dengue virus Species 0.000 title claims abstract description 71
- 238000000034 method Methods 0.000 title claims abstract description 38
- 238000002347 injection Methods 0.000 claims abstract description 25
- 239000007924 injection Substances 0.000 claims abstract description 25
- 206010012310 Dengue fever Diseases 0.000 claims description 14
- 208000025729 dengue disease Diseases 0.000 claims description 14
- 208000001490 Dengue Diseases 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 230000002238 attenuated effect Effects 0.000 claims description 9
- 230000002163 immunogen Effects 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 239000003446 ligand Substances 0.000 claims 6
- 101710146739 Enterotoxin Proteins 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 239000000147 enterotoxin Substances 0.000 claims 2
- 231100000655 enterotoxin Toxicity 0.000 claims 2
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 claims 1
- 229920001202 Inulin Polymers 0.000 claims 1
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 claims 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims 1
- 229960002751 imiquimod Drugs 0.000 claims 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims 1
- 229940029339 inulin Drugs 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 claims 1
- 241000710829 Dengue virus group Species 0.000 abstract description 9
- 238000002255 vaccination Methods 0.000 abstract description 5
- 230000003472 neutralizing effect Effects 0.000 description 28
- 241001465754 Metazoa Species 0.000 description 25
- 241000700605 Viruses Species 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 21
- 238000009472 formulation Methods 0.000 description 21
- 230000003053 immunization Effects 0.000 description 20
- 238000002649 immunization Methods 0.000 description 20
- 230000005875 antibody response Effects 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 230000004044 response Effects 0.000 description 8
- 206010058874 Viraemia Diseases 0.000 description 7
- 230000005847 immunogenicity Effects 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 101000619564 Homo sapiens Putative testis-specific prion protein Proteins 0.000 description 5
- 102100022208 Putative testis-specific prion protein Human genes 0.000 description 5
- 108020000999 Viral RNA Proteins 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 230000029812 viral genome replication Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 3
- 241000282567 Macaca fascicularis Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229940023605 dengue virus vaccine Drugs 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 229960004854 viral vaccine Drugs 0.000 description 3
- 241000478345 Afer Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 210000001821 langerhans cell Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 244000005894 Albizia lebbeck Species 0.000 description 1
- 206010003399 Arthropod bite Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000191823 Cynomys Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000005101 cell tropism Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940090046 jet injector Drugs 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- KJLLKLRVCJAFRY-UHFFFAOYSA-N mebutizide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)NC(C(C)C(C)CC)NC2=C1 KJLLKLRVCJAFRY-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002991 molded plastic Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 238000002962 plaque-reduction assay Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 208000029556 susceptibility to dengue virus Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18302009P | 2009-06-01 | 2009-06-01 | |
| PCT/US2010/036726 WO2010141386A1 (en) | 2009-06-01 | 2010-05-28 | Compositions and methods for administration of vaccines against dengue virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG176299A1 true SG176299A1 (en) | 2012-01-30 |
Family
ID=43220488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2011088788A SG176299A1 (en) | 2009-06-01 | 2010-05-28 | Compositions and methods for administration of vaccines against dengue virus |
Country Status (17)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013188315A1 (en) * | 2012-06-10 | 2013-12-19 | Inviragen, Inc. | Compositions and methods for administration of vaccines against dengue virus |
| US8968996B2 (en) | 2009-06-01 | 2015-03-03 | Takeda Vaccines, Inc. | Compositions and methods for rapid immunization against dengue virus |
| CN102449172A (zh) | 2009-06-01 | 2012-05-09 | 伊维拉根公司 | 施用针对登革病毒的疫苗的组合物和方法 |
| EP2931310A4 (en) * | 2012-12-14 | 2016-05-25 | Takeda Vaccines Inc | COMPOSITIONS, METHODS OF ADMINISTRATION AND USES OF TRIVALENT FORMULATIONS AGAINST DENGUE VIRUS |
| CA3177574C (en) | 2013-03-15 | 2026-03-31 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for dengue virus chimeric constructs in vaccines |
| JP2019511533A (ja) | 2016-04-13 | 2019-04-25 | タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. | 小児及び若年成人のデングウイルスに対するワクチンの組成物及び方法 |
| CA3086456A1 (en) | 2017-12-21 | 2019-06-27 | Kirin Holdings Kabushiki Kaisha | Cross-immunizing antigen vaccine and method for preparation thereof |
| US11426461B2 (en) | 2018-09-05 | 2022-08-30 | Takeda Vaccines, Inc. | Methods for preventing dengue and hepatitis A |
| US11590221B2 (en) | 2018-09-05 | 2023-02-28 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
| US11464815B2 (en) | 2018-09-05 | 2022-10-11 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
| GB202011055D0 (en) * | 2020-07-17 | 2020-09-02 | Ipsen Bioinnovation Ltd | Treatment of post-operative pain |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0872553B1 (en) * | 1991-09-19 | 2000-11-15 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the Secretary of the Department of HEALTH AND HUMAN SERVICES | Chimeric and/or growth-restricted flaviviruses |
| FR2741077B1 (fr) * | 1995-11-14 | 1998-01-23 | Pasteur Institut | Vaccin polyvalent anti-dengue |
| AU779280B2 (en) * | 1999-03-26 | 2005-01-13 | Walter Reed Army Institute Of Research | Multivalent dengue virus vaccine |
| DK2278012T3 (en) | 2000-02-16 | 2015-12-07 | Us Government | Immunogenic dengue 2 virus chimeras |
| EP1159969A1 (fr) * | 2000-05-30 | 2001-12-05 | Aventis Pasteur | Vaccine composition |
| CA2755964C (en) | 2001-05-22 | 2017-06-27 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses |
| GB0123580D0 (en) * | 2001-10-01 | 2001-11-21 | Glaxosmithkline Biolog Sa | Vaccine |
| US20040120964A1 (en) * | 2001-10-29 | 2004-06-24 | Mikszta John A. | Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses |
| AU2003239932A1 (en) * | 2002-05-31 | 2003-12-19 | Acambis, Inc. | Tetravalent dengue vaccines |
| SG156666A1 (en) * | 2004-10-20 | 2009-11-26 | Acambis Inc | Vaccines against japanese encephalitis virus and west nile virus |
| US8110196B2 (en) | 2005-04-29 | 2012-02-07 | Polytopas LLC | Methods and compositions for polytopic vaccination |
| US7618393B2 (en) * | 2005-05-03 | 2009-11-17 | Pharmajet, Inc. | Needle-less injector and method of fluid delivery |
| DE602006015807D1 (de) * | 2005-06-17 | 2010-09-09 | Ct S For Disease Control & Pre | Abgeschwächter dengue-serotyp-2-stamm |
| WO2007021672A2 (en) * | 2005-08-10 | 2007-02-22 | Acambis Inc. | Vaccination against dengue virus infection |
| ZA200802176B (en) * | 2005-08-10 | 2009-08-26 | Acambis Inc | Vaccination against dengue virus infection |
| DK2054428T3 (da) * | 2006-08-15 | 2013-08-26 | Government Of The U S A As Repr By The Secretary Dept Of Health & Human Services The Nat Inst Of Hea | Udvikling af bestanddele til denque-virus-vaccine |
| FR2906724B1 (fr) * | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
| FR2909286B1 (fr) * | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
| WO2008085288A1 (en) * | 2007-01-11 | 2008-07-17 | Sealed Air Corporation (Us) | Method of shaping insulation |
| US20100316670A1 (en) | 2007-06-14 | 2010-12-16 | Blaney Joseph E | Chimeric sle/dengue type 4 antigenic viruses |
| US8968996B2 (en) | 2009-06-01 | 2015-03-03 | Takeda Vaccines, Inc. | Compositions and methods for rapid immunization against dengue virus |
| CN102449172A (zh) | 2009-06-01 | 2012-05-09 | 伊维拉根公司 | 施用针对登革病毒的疫苗的组合物和方法 |
-
2010
- 2010-05-28 CN CN2010800241489A patent/CN102449172A/zh active Pending
- 2010-05-28 MX MX2011012807A patent/MX343172B/es active IP Right Grant
- 2010-05-28 NZ NZ618158A patent/NZ618158A/en not_active IP Right Cessation
- 2010-05-28 JP JP2012513332A patent/JP5848243B2/ja not_active Expired - Fee Related
- 2010-05-28 AU AU2010256845A patent/AU2010256845B2/en not_active Ceased
- 2010-05-28 CN CN201711026301.1A patent/CN107913406A/zh active Pending
- 2010-05-28 CA CA2763944A patent/CA2763944A1/en not_active Abandoned
- 2010-05-28 KR KR1020117031022A patent/KR101876304B1/ko not_active Expired - Fee Related
- 2010-05-28 WO PCT/US2010/036726 patent/WO2010141386A1/en not_active Ceased
- 2010-05-28 NZ NZ597000A patent/NZ597000A/en not_active IP Right Cessation
- 2010-05-28 EP EP10783881.5A patent/EP2438198A4/en not_active Withdrawn
- 2010-05-28 SG SG2011088788A patent/SG176299A1/en unknown
- 2010-05-28 MY MYPI2011005768A patent/MY184428A/en unknown
- 2010-05-28 US US12/790,511 patent/US9211323B2/en not_active Expired - Fee Related
-
2011
- 2011-11-29 CU CU20110219A patent/CU20110219A7/es unknown
- 2011-11-30 IL IL216706A patent/IL216706A0/en not_active IP Right Cessation
- 2011-12-01 CL CL2011003043A patent/CL2011003043A1/es unknown
- 2011-12-12 CO CO11170641A patent/CO6470882A2/es not_active Application Discontinuation
-
2015
- 2015-11-06 US US14/935,281 patent/US10010600B2/en not_active Expired - Fee Related
- 2015-11-26 JP JP2015230723A patent/JP2016033151A/ja active Pending
- 2015-12-17 IL IL243204A patent/IL243204A0/en unknown
-
2016
- 2016-12-05 PH PH12016502431A patent/PH12016502431A1/en unknown
- 2016-12-22 AU AU2016277660A patent/AU2016277660A1/en not_active Abandoned
-
2019
- 2019-01-11 AU AU2019200212A patent/AU2019200212A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2438198A4 (en) | 2014-05-14 |
| CN107913406A (zh) | 2018-04-17 |
| CA2763944A1 (en) | 2010-12-09 |
| US9211323B2 (en) | 2015-12-15 |
| EP2438198A1 (en) | 2012-04-11 |
| KR101876304B1 (ko) | 2018-07-10 |
| AU2016277660A1 (en) | 2017-01-12 |
| US20160129102A1 (en) | 2016-05-12 |
| WO2010141386A1 (en) | 2010-12-09 |
| NZ597000A (en) | 2014-07-25 |
| IL243204A0 (en) | 2016-02-29 |
| KR20120027396A (ko) | 2012-03-21 |
| JP2012528794A (ja) | 2012-11-15 |
| CO6470882A2 (es) | 2012-06-29 |
| IL216706A0 (en) | 2012-02-29 |
| JP2016033151A (ja) | 2016-03-10 |
| NZ618158A (en) | 2015-05-29 |
| AU2010256845A1 (en) | 2011-12-22 |
| CL2011003043A1 (es) | 2012-07-20 |
| JP5848243B2 (ja) | 2016-01-27 |
| PH12016502431A1 (en) | 2019-02-11 |
| US10010600B2 (en) | 2018-07-03 |
| CU20110219A7 (es) | 2012-06-21 |
| AU2010256845B2 (en) | 2016-09-22 |
| MY184428A (en) | 2021-04-01 |
| MX343172B (es) | 2016-10-26 |
| AU2019200212A1 (en) | 2019-01-31 |
| CN102449172A (zh) | 2012-05-09 |
| MX2011012807A (es) | 2012-01-30 |
| US20100303860A1 (en) | 2010-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2010256845B2 (en) | Compositions and methods for administration of vaccines against dengue virus | |
| US8968996B2 (en) | Compositions and methods for rapid immunization against dengue virus | |
| US11975067B2 (en) | Coronavirus disease (COVID-19) vaccine | |
| Erasmus et al. | Development of vaccines for chikungunya fever | |
| EP2858668A1 (en) | Compositions and methods for administration of vaccines against dengue virus | |
| JP2016501850A (ja) | 口蹄疫（ｆｍｄ）に対する合成ペプチドベースの緊急ワクチン | |
| Collen et al. | Heterotypic recognition of recombinant FMDV proteins by bovine T-cells: the polymerase (P3Dpol) as an immunodominant T-cell immunogen | |
| AU2018278927A1 (en) | Methods and compositions for dengue virus vaccines | |
| CN102168088B (zh) | T细胞免疫原基因ti及其在口蹄疫蛋白亚单位疫苗和灭活疫苗中的应用 | |
| Choudhury et al. | Recent development of ruminant vaccine against viral diseases | |
| Giel-Moloney et al. | A novel approach to a rabies vaccine based on a recombinant single-cycle flavivirus vector | |
| Forner | Multi-epitope peptide platforms for vaccine applications | |
| Tsiang | Rabies vaccines: a review of progress towards improved efficacy and safety | |
| Ertl | to Recombinant Biologics for Humans and Companion Animals | |
| Gomase et al. | Vaccinomics. |